Division of Digestive Disease, University of California Los Angeles Health, Los Angeles, California, USA.
Division of Gastroenterology and Hepatology, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
Am J Gastroenterol. 2019 Apr;114(4):679-683. doi: 10.14309/ajg.0000000000000134.
To familiarize medical providers with the Food and Drug Administration approval process for antiobesity devices and to provide a brief overview of current and promising endoscopy-based bariatric devices.
Literature review of published scholarly articles.
There has been a rapid development of novel endoscopic bariatric therapies in recent years, resulting in the approval of multiple devices. Several promising endoscopic strategies are currently under investigation and review. The Food and Drug Administration has laid down an objective-tiered model to review antiobesity device applications.
Endoscopic bariatric devices provide a new and promising paradigm in obesity management both as first-line therapy and as adjunctive treatment to medical and surgical strategies. Physicians who plan to offer endoscopic bariatric therapy in their practice need appropriate understanding of the regulatory processes involved in the development and approval of such devices.
使医疗服务提供者熟悉食品和药物管理局对减肥药的审批程序,并简要介绍当前和有前途的基于内镜的减肥设备。
对已发表的学术文章进行文献回顾。
近年来,新型内镜减肥疗法发展迅速,多个设备获得批准。目前正在研究和审查几种有前途的内镜策略。食品和药物管理局已经制定了一个客观的分层模型来审查减肥药的应用。
内镜减肥设备为肥胖症管理提供了一种新的、有前途的模式,既可以作为一线治疗,也可以作为医疗和手术策略的辅助治疗。计划在实践中提供内镜减肥治疗的医生需要适当了解此类设备开发和批准所涉及的监管程序。